Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain
Datos Bibliográficos
| ID | 9101596 |
|---|---|
| Autores | Jill A Bell (Purdue Pharma L.P., Stamford, CT, autor de correspondencia), Marco daCosta DiBonaventura (Health Outcomes Practice, Kantar Health, New York, NY), Marco DiBonaventura (0000-0002-8333-4676, Kantar Health (United States)), Edward A Witt (0000-0002-5883-9701, Health Outcomes Practice, Kantar Health, New York, NY), Rami Ben-Joseph (Purdue Pharma L.P., Stamford, CT), Rami Ben‐Joseph (Purdue Pharma (United States), autor de correspondencia), Bryce B Reeve (0000-0002-6709-8714, Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC) |
| Año | 2017 |
| Volumen | 55 |
| Número | 2 |
| Páginas | 111-116 |
| Fecha de publicación | 2017-02-01 |
| Peer Reviewed | Sí |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Medical Care (JOURNAL) |
| Identificadores de la revista | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Editorial | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000000617 |
| PMID | 27517330 |
| OpenAlex | W2518452678 |
| Idioma | EN |
| Referencias citadas | 21 |
STUDY OBJECTIVES: To assess the feasibility of using the SF-36v2 mental health (MH) and mental component summary (MCS) scores for classification of risk for major depressive disorder (MDD), and to determine cut-off scores based on the sensitivity and specificity in a general US representative sample, and a chronic pain subpopulation. METHODS: Data were analyzed from the 2013 US National Health and Wellness Survey (adults 18 y old and above; N=75,000), and among a chronic pain subpopulation (n=6679). Risk of MDD was a score ≥10 on the Patient Health Questionnaire (PHQ-9). Logistic regression modeling was used to predict at risk for MDD and receiver operating characteristic curves were produced. RESULTS: The total sample had MH scores of 48.8 and MCS scores of 48.9, similar to the normative US population mean. Percent of respondents with a PHQ-9≥10 were 15.0% and 29.1% for the total sample and chronic pain subpopulation, respectively. Cut-off scores (PHQ-9≥10) in the total sample for the MH and MCS were 43.0 and 46.0, respectively. Specificities for the MH and MCS were 77.8% and 76.1%; sensitivities were 84.9% and 88.1%, respectively. Among the subpopulation with chronic pain, cut-off scores for the MH and MCS were 40.4 and 43.1, respectively. Corresponding specificities for the MH and MCS were 77.9% and 73.9%; sensitivities were 78.3% and 83.4%, respectively. CONCLUSIONS: The SF-36v2 was found to have sufficient specificity and sensitivity to categorize participants at risk for MDD. If no depression questionnaire is available, it is feasible to use the SF-36v2 to characterize the MH of populations
Anxiety · Chronic pain · Depressive symptoms · Environmental health · Major depressive disorder · Population · Psychiatry · Sample (material) · Cardiac Health and Mental Health · Medicine · Mental Health Treatment and Access · Psychology · Treatment of Major Depression
Measuring the mental health status of the Norwegian population
The PHQ-9
A new method of classifying prognostic comorbidity in longitudinal studies
Performance of the SF-36 Health Survey in screening for depressive and anxiety disorders in an elderly female Swedish population
Association of insomnia with quality of life, work productivity, and activity impairment
A Short, Psychiatric, Case-Finding Measure for HIV Seropositive Outpatients
Performance of a Five-Item Mental Health Screening Test
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |